|
Sep 25
|
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
|
|
Aug 2
|
Q2 2024 Arbutus Biopharma Corp Earnings Call
|
|
Aug 1
|
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 1
|
Arbutus: Q2 Earnings Snapshot
|
|
Aug 1
|
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
|
Jun 6
|
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
|
|
Jun 6
|
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
|
|
Jun 5
|
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
|
|
Jan 1
|
Institutions own 30% of Arbutus Biopharma Corporation (NASDAQ:ABUS) shares but individual investors control 32% of the company
|
|
Oct 24
|
Will Arbutus Biopharma (NASDAQ:ABUS) Spend Its Cash Wisely?
|
|
Oct 24
|
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
|
|
Oct 18
|
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
|
|
Sep 7
|
Arbutus to Participate in Two Upcoming Investor Conferences
|
|
Aug 4
|
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript
|
|
Aug 3
|
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
|
|
Aug 3
|
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
|